Zoledronic acid to prevent bone loss from HIV treatment
Treatments studied
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This trial tests if zoledronic acid, a drug that strengthens bones, can prevent bone loss caused by starting HIV treatment. It is for people newly diagnosed with HIV who have not yet taken any HIV medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Diagnosed with HIV
- Never taken medication to prevent or treat HIV
- Not pregnant, breastfeeding, or planning to become pregnant
- No history of severe reaction to bisphosphonate drugs (like severe jaw bone problems or unusual thigh breaks)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how the body handles a medicine called zoledronic acid in people with kidney disease who are on dialysis and have weak bones (osteoporosis). It may help doctors find the right dose to safely treat bone loss in this group.
This trial tests if a bone-strengthening drug called zoledronic acid can help people with congenital dyserythropoietic anemia (CDA), a rare type of anemia. It's for adults with moderate to severe anemia who may also need blood transfusions.
This real-world study looks at how the medicine zoledronic acid affects bone-related problems in people with breast cancer that has spread to the bone. It may help reduce events like fractures or other bone complications by protecting bone health.
This study tests if alendronate, a bone-strengthening medicine, can shrink the reservoir of HIV that stays in your body even when on treatment. You must have well-controlled HIV on antiretroviral therapy for at least one year but no more than ten years, and meet specific health requirements.
This Phase 2 study tests whether zoledronic acid or denosumab can prevent bone thinning in critically ill adults after staying in the ICU. It may help reduce the risk of future bone fractures if your body is at higher risk during and after critical illness.
This trial tests whether giving zoledronic acid (a bone-strengthening infusion) right after stopping denosumab can help prevent bone loss in women with post-menopausal osteoporosis. It may be a good option if you have finished at least 2 years of denosumab and your doctor says it's safe to stop.
Hear when a new HIV Infected Individuals trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.